stockportfolio.pro
Zimmer Biomet Holdings, Inc. (ZBH)
Healthcare · Medical Devices · NYSE
Zimmer Biomet Holdings, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.67B | $7.80B | $7.93B | $7.98B | $6.13B | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B |
| Gross profit | $5.29B | $5.67B | $5.66B | $5.73B | $4.30B | $4.87B | $4.92B | $5.31B | $5.49B | $5.74B |
| Net income | $305.90M | $1.81B | $-379.20M | $1.13B | $-138.90M | $401.60M | $231.40M | $1.02B | $903.80M | $705.10M |
| Net margin | 4.0% | 23.2% | -4.8% | 14.2% | -2.3% | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
Source: Zimmer Biomet Holdings, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into ZBH stock?
At today's market cap of $17.34B, Zimmer Biomet Holdings, Inc. is priced for free-cash-flow growth of about 0.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.47B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 6.2%/yr over the last five fiscal years and revenue 6.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Zimmer Biomet Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ZBH in your portfolio →
Zimmer Biomet Holdings, Inc. financial history by metric
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Zimmer Biomet Holdings, Inc. — frequently asked questions
What is Zimmer Biomet Holdings, Inc.'s revenue?
Zimmer Biomet Holdings, Inc. (ZBH) reported revenue of $8.23B for fiscal year 2025, up 7.2% from the prior year, according to its SEC filings.
Is Zimmer Biomet Holdings, Inc. profitable?
Yes. ZBH earned net income of $705.10M in fiscal 2025, a net margin of 8.6%.
What is ZBH's P/E ratio?
Zimmer Biomet Holdings, Inc. trades at a price-to-earnings ratio of about 23.2 based on the latest data in our nightly-refreshed cache.
How fast is Zimmer Biomet Holdings, Inc. growing?
ZBH's revenue grew at roughly 6.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Zimmer Biomet Holdings, Inc. have?
As of fiscal year 2025, ZBH carried roughly $6.93B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Zimmer Biomet Holdings, Inc.'s gross margin?
ZBH's gross margin was 69.7% in fiscal 2025 — gross profit of $5.74B on revenue of $8.23B.
What is Zimmer Biomet Holdings, Inc.'s market cap?
Zimmer Biomet Holdings, Inc. (ZBH) has a market capitalization of about $17.34B, based on the latest data in our nightly-refreshed cache.
When does Zimmer Biomet Holdings, Inc.'s fiscal year end?
ZBH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ZBH stock?
At today's market cap of $17.34B, Zimmer Biomet Holdings, Inc. is priced for free-cash-flow growth of about 0.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.47B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 6.2%/yr over the last five fiscal years and revenue 6.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Zimmer Biomet Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.